Navigation Links
Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference
Date:10/8/2009

SAN DIEGO, Oct. 8 /PRNewswire/ -- Adnavance Technologies Inc., a developer of direct detection molecular diagnostic tests for medical applications, announced today that Randy White, Ph.D. chief executive officer, will present initial data supporting direct detection of DNA targets in human clinical samples during company presentations at the following conferences:

  • AdvaMed 2009 on Tuesday, October 13, 2009 at 10:00 a.m. Eastern Time at the Walter E. Washington Convention Center in Washington, D.C.
  • BIOCOM's 4th Annual Investor Conference on Monday, October 26, 2009 at 10:00 a.m. Pacific Time at the Hyatt Regency La Jolla in San Diego, California.

"The hallmark of Adnavance's direct detection technology is its simplicity; it doesn't require PCR, light detection, or sample pre-treatment. We are highly encouraged by our initial data supporting the utility of our technology and its potential for use in medium complexity laboratories," said Dr. White. "Our mission is to de-centralize molecular diagnostics."

About Adnavance Technologies Inc.

Adnavance is a molecular diagnostic company focused on development of its proprietary technology that allows direct-detection of DNA targets in human clinical samples. The Company is located in San Diego, CA. The Company's patented technology is based on the change in surface charge on a gold electrode when DNA targets hybridize with capture probes anchored to the electrode surface. The Company uses a microarray of electrodes in an electrochemical cell to detect the target DNA and the inherent ultra-sensitivity of electrochemical measurements obviates the need for target amplification used in current molecular-based tests. In addition, the electrochemical measurement simplifies the medical device and eliminates sample pre-treatment steps required for PCR-based tests. Adnavance scientists were the first to discover the surface charge phenomenon, and the Company believes its technology platform will open new molecular testing markets. For additional information please see the Company website at www.adnavance.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate," and similar words indicating uncertainty in facts and figures. Although Adnavance believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove correct. Actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with the technology development process, the risk that Adnavance technology will not gain market acceptance, the risks associated with dependence upon key personnel and the need for additional financing to commercialize the technology platform.

    Media Contact:
    Kim Richards
    Porter Novelli Life Sciences
    619-849-5377
    krichards@pnlifesciences.com

SOURCE Adnavance Technologies Inc.


'/>"/>
SOURCE Adnavance Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Noninvasive Medical Technologies Awarded ISO 13485 Quality Certification
2. ReBuilder Medical Technologies, Inc. Hiring! Increases Staff by 40%
3. Wound Management Technologies Acquires Resorbable Orthopedics
4. Blue Belt Technologies, Inc. Closes Series A Financing
5. ReBuilder Medical Technologies, Inc. Reports LOI With National DME Distributor
6. Pre-clinical Data Show OrbusNeichs Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
7. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
8. IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent
9. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
10. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
11. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
(Date:4/27/2016)... 27, 2016 Oasmia Pharmaceutical ... of a new generation of drugs within human ... results for Paclical/Apealea in the Phase III study ... epithelial ovarian cancer. These preliminary results showed non-inferiority ... with carboplatin versus Taxol in combination with carboplatin. ...
(Date:4/27/2016)... , April 27, 2016 ... reach USD 2.06 billion by 2022, according to ... Increasing consumer awareness towards a healthy lifestyle is ... seven years.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... coupled with rising health treatment expenditure has urged ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... ... the open availability of a new CDISC standard, Clinical Trial Registry (CTR) ... trials. This innovative standard will make it possible to build applications that ...
(Date:4/28/2016)... ... April 28, 2016 , ... Trinity Health, one ... a leading force in the fight to reduce tobacco use and its deadly ... can help reduce tobacco use. The initiative brings together two organizations committed to ...
(Date:4/28/2016)... ... April 28, 2016 , ... In 2011, TIME magazine named Herr the “Leader ... biomechatronics, technology that marries human physiology with electromechanics. He continues that work as Director ... Founder of BionX , a leader in the field of prosthetic devices. , ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cognizin® Citicoline is one of ... in the Healthy Ageing category, Cognizin® is being considered for this prestigious honor ... can include everything from antioxidants, lipids, proteins, and botanicals. NutraIngredients will choose a ...
(Date:4/28/2016)... ... ... Card reminds us that May is National Stroke Awareness Month. According to the Centers ... in the United States; someone has one every 40 seconds. Annually, almost 800,000 strokes ... old. A stroke is when blood flow to the brain is blocked or when ...
Breaking Medicine News(10 mins):